Which cancers does Larotinib/Larotinib treat?

Larotrectinib is known to be a kinase inhibitor./Larotrectinib is known to be a kinase inhibitor. A kinase is an enzyme that promotes cell growth. There are many types of kinases in the body that control different stages of cell growth. Larotrectinib works as a substance to slow the growth of cancer cells in the body by blocking a specific enzyme from working. Larotrectinib only works in tumors with certain NTRK (neurotrophin tropomyosin receptor kinase) genes. Therefore, doctors must determine the presence of this gene mutation before giving larotrectinib to patients.

Larotinib developed by Loxo Oncology is a TRK inhibitor that was approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of solid tumors with NTRK gene fusions in adults and children. It is a chiral pyrazolo[1,5-a]pyrimidine derivative with an Adifluorinated benzyl ring, which exhibits high selectivity and potency for TRKA/B/C in in vitro experiments, with IC50 values u200bu200bin the low nanomolar range. The efficacy of larotrectinib was evaluated in three clinical trials in 55 patients aged 4 months to 76 years with unresectable or metastatic solid tumors associated with NTRK gene fusions. Adult patients take larotrectinib orally twice a day at a dose of 100 mg, and pediatric patients ≤18 years old take 100 mg/m2 orally daily (the maximum dose is 100 mg twice a day).

Independent review showed the overall response rate was 75%, while investigator assessment showed the overall response rate was 80%. After one year, sustained responses were observed in 71% of patients and progression-free survival was observed in 55% of patients. At a median follow-up of 9.4 months, 86% of responding patients were undergoing treatment or curative surgery. Adverse reactions were primarily grade 1; investigators observed no grade 3 or 4 adverse reactions related to larotrectinib in more than 5% of patients. No patients discontinued larotrectinib due to drug-related adverse events.